









Markets
/
Stocks
/
nasdaq-aclx
/

Arcellx Inc

ACLX

85.690USD

-0.860-0.99%

Close 11/10, 16:00（ET）Quotes delayed by 15 min

4.95BMarket Cap

LossP/E TTM



Arcellx Inc

85.690

-0.860-0.99%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Arcellx Inc

Currency: USD Updated: 2025-11-10

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Arcellx Inc's Score

Industry at a Glance

Industry Ranking

30 / 407

Overall Ranking

114 / 4611

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 19 analysts

Buy

Current Rating

113.000

Target Price

+30.56%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Arcellx Inc Highlights

StrengthsRisks

Arcellx, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of controllable cell therapies for the treatment of patients with cancer and other incurable diseases. The Company’s lead program is a BCMA-targeting ddCAR product candidate called CART-ddBCMA, which is being evaluated in its pivotal Phase II iMMagine-1 trial in patients with relapsed or refractory multiple myeloma (rrMM). The Company is also developing two clinical-stage ARC-SparX programs in Phase I trials; ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Outside of multiple myeloma (MM), the Company advances its wholly owned portfolio of clinical-stage, ACLX-002, and preclinical pipeline programs incorporating its D-Domain technology. D-Domain, is designed to overcome the limitations of traditional Chimeric Antigen Receptor T-cells (CAR-Ts).

Fairly Valued

The company’s latest PE is -21.76, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 58.68M shares, decreasing 3.26% quarter-over-quarter.

Held by Ron Baron

Star Investor Ron Baron holds 518.01K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-10

The company's current financial score is 7.13, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 4.95M, representing a year-over-year decrease of 80.99%, while its net profit experienced a year-over-year decrease of 115.65%.

Score

Industry at a Glance

Previous score

7.13

Change



Financials

5.19

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.43

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.79

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.23

Key Metrics

Free cash flow

No Data

Arcellx Inc's Company Valuation

Currency: USD Updated: 2025-11-10

The company’s current valuation score is 7.10, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -21.76, which is -76.17% below the recent high of -5.19 and -594.09% above the recent low of -151.06.

Score

Industry at a Glance

Previous score

7.10

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 30/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-10

The company’s current earnings forecast score is 8.63, which is higher than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Arcellx Inc is 112.00, with a high of 134.00 and a low of 88.00.

Score

Industry at a Glance

Previous score

8.63

Change

Support & Resistance

No Data

Analyst Rating

Based on 19 analysts

Buy

Current Rating

113.000

Target Price

+30.56%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Arcellx Inc

ACLX

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-10

The company’s current price momentum score is 6.98, which is higher than the Biotechnology & Medical Research industry's average of 6.59. Sideways: Currently, the stock price is trading between the resistance level at 92.30 and the support level at 80.86, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.11

Change

-0.13

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.885

Neutral

RSI(14)

50.339

Neutral

STOCH(KDJ)(9,3,3)

30.191

Sell

ATR(14)

3.716

High Vlolatility

CCI(14)

0.488

Neutral

Williams %R

68.486

Sell

TRIX(12,20)

0.210

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

87.226

Sell

MA10

87.353

Sell

MA20

87.014

Sell

MA50

82.134

Buy

MA100

75.663

Buy

MA200

69.979

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-10

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.13. The latest institutional shareholding proportion is 101.48%, representing a quarter-over-quarter decrease of 12.08%. The largest institutional shareholder is The Vanguard, holding a total of 3.90M shares, representing 6.75% of shares outstanding, with 9.79% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Gilead Sciences Inc

6.72M

T. Rowe Price Investment Management, Inc.

6.28M

+222.88%

Fidelity Management & Research Company LLC

5.57M

-4.52%

Paradigm BioCapital Advisors LP

4.65M

+3.49%

The Vanguard Group, Inc.

Star Investors

3.94M

-1.01%

New Enterprise Associates (NEA)

3.05M

-18.69%

RA Capital Management, LP

3.04M

BlackRock Institutional Trust Company, N.A.

2.77M

-13.63%

Vestal Point Capital, LP

2.75M

+15.17%

Perceptive Advisors LLC

2.48M

-15.32%

Risk Assessment

Currency: USD Updated: 2025-11-10

The company’s current risk assessment score is 7.32, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.34. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.